Analysis of COVID-19-Global Antiviral Drugs Market 2020-2024 | Evolving Opportunities with AbbVie Inc. and Bristol-Myers Squibb Co. | Technavio

Technavio has announced the latest market research report titled Global Antiviral Drugs Market 2020-2024 (Graphic: Business Wire)

LONDON--()--The global antiviral drugs market is expected to grow by USD 43.37 billion as per Technavio. Despite the impact of the COVID-19 pandemic, the growth for this market is expected to remain steady in the first half of 2020 and throughout the forecast period.

Request for Technavio's latest reports on directly and indirectly impacted markets
Market estimates include pre- and post-COVID-19 impact on the antiviral drugs market -

Download free sample report

As of March 2020, the novel Coronavirus (COVID-19) outbreak has resulted in more than 21,000 casualties throughout the globe. The severity of the pandemic and the rising death toll has necessitated the development of breakthrough antiviral drugs, creating an ample market opportunity for pharmaceutical companies. Public health agencies such as the WHO, National Institute of Health (NIH), and the CDC serve key information sources that are used by manufacturers to obtain vital information about COVID-19, thus helping them ramp up their research activities for the development of vaccines.

Technavio's custom research reports offer detailed insights on the impact of COVID-19 at an industry level, a regional level, and subsequent supply chain operations. This customized report will also help clients keep up with new product launches in direct & indirect COVID-19 related markets, upcoming vaccines and pipeline analysis, and significant developments in vendor operations and government regulations.

The market is driven by the growing cases of viral infections. In addition, technological advancements are anticipated to boost the growth of the antiviral drugs market.

The incidence of HIV infection is increasing across the globe. According to the CDC, approximately 800,000 to 1.4 million people are infected with hepatitis B each year. Similarly, the recent COVID-19 outbreak has created a panic around the world. The unprecedented growth in the global aging population coupled with increasing mortality rate, caused by aforementioned diseases and other viral infections is accelerating the demand for efficacious, single-dose tablet regimens. This is propelling vendors to develop effective antiviral drugs, thus driving the market growth during the forecast period.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Antiviral Drugs Companies:

AbbVie Inc.

AbbVie Inc. operates the business under the Pharmaceutical products segment. The company offers MAVYRET. It is a once-daily, ribavirin-free treatment for adults with chronic hepatitis C virus infection across all major genotypes.

Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co. offers products through the Biopharmaceuticals segment. The company is engaged in the discovery, development, licensing, manufacture, marketing, distribution, and sale of innovative medicines that help patients prevail over serious diseases. They offer Daklinza, which is a medication used in combination with other medications to treat hepatitis C.

F. Hoffmann-La Roche Ltd.

F. Hoffmann-La Roche Ltd. operates under various business segments, namely Pharmaceuticals and Diagnostics. The company offers XOFLUZA, which is used as an antiviral medication for treatment of influenza A and influenza B flu.

Gilead Sciences Inc.

Gilead Sciences Inc. offers products through the Pharmaceuticals business segment. The company focuses on the discovery, development, and commercialization of innovative medicines for various indications. They provide COMPLERA, which is used to treat HIV in people who have never taken HIV medicines before.

GlaxoSmithKline Plc

GlaxoSmithKline Plc offers products through the following business segments: Pharmaceuticals, Consumer healthcare, and Vaccines. The company offers Triumeq, which is a fixed-dose combination medication for the treatment of HIV/AIDS.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Antiviral Drugs Market Application Outlook (Revenue, USD Billion, 2020-2024)

  • Hepatitis
  • HIV
  • Herpes
  • Influenza
  • Others

Antiviral Drugs Market Geographic Landscape Outlook (Revenue, USD Billion, 2020-2024)

  • Asia
  • Europe
  • North America
  • ROW
  • Key leading countries

Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200

Release Summary

The antiviral drugs market size has the potential to grow by USD 43.37 billion during 2020-2024


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200